


MAY 25 2004

Practitioner's Docket No. 044481-5029-02-US (MPI97-068P1CN1DV1M)
703-872-9306

PATENT

OFFICIAL

Certificate of Transmission under 37 CFR 1.8

I hereby certify that this correspondence is being facsimile transmitted to the
United States Patent and Trademark Officeon May 25, 2004
Signature
Simonne Corriveau
Typed or printed name of person signing Certificate

Submitted herewith:

Revocation Transmittal Letter	(2 pages)
Revocation of Prior Powers of Attorney and	
Appointment of New Power of Attorney	(2 pages)
Change of Attorney Docket Number	(1 page)
Associate Power of Attorney and	
Appendix A - Statement of Limited Recognition for	
Mario Cloutier under 37 CFR §10.9(b)	(3 pages)
Statement of Limited Recognition for	
Mario Cloutier under 37 CFR §10.9(b)	(1 page)
 Total	 Pages (10 pages) (including this cover sheet)

TO/SB/97 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Practitioner's Docket No. 044481-5029-02-US (MPI97-068P1CN1DV1M)

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:	Storm, Daniel R., et al		
Application No.:	10/071,223	Group No.:	1652
Filed:	February 11, 2002	Examiner:	David J. Steadman, Ph.D.
For:	CLONING AND CHARACTERIZATION OF A HUMAN ADENYLYL CYCLASE		

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

REVOCATION TRANSMITTAL

1. Transmitted herewith for this application is:
 - a. This Transmittal (2 pages);
 - b. Revocation of Prior Power of Attorney and Appointment of New Power of Attorney (2 pages); and
 - c. Change of Attorney Docket Number (1 page)
 - d. Associate Power of Attorney (2 pages) and Appendix A - Statement of Limited Recognition for Mario Cloutier under 37 CFR §10.9(b) (1 page);
 - e. Statement of Limited Recognition under 37 CFR §10.9(b) for Mario Cloutier (1 page)

STATUS

2. Applicant is other than a small entity.

CERTIFICATION UNDER 37 C.F.R. SECTIONS 1.8(a) and 1.10*

I hereby certify that, on the date shown below, this correspondence is being:

MAILING

- ☐ deposited with the United States Postal Service in an envelope addressed to the Commissioner for Patents, Washington, D.C. 20231.

37 C.F.R. SECTION 1.8(a)

37 C.F.R. SECTION 1.10*

- ☐ with sufficient postage as first class mail.

- ☐ as "Express Mail Post Office to Addressee"
Mailing Label No.

TRANSMISSION

- ☒ transmitted by facsimile to the Patent and Trademark Office to (703) 572 9306.


Signature
Simonne Corriveau

(type or print name of person certifying)

Date: May 25, 2004

*WARNING: Each paper or fee filed by "Express Mail" must have the number of the "Express Mail" mailing label placed thereon prior to mailing. 37 C.F.R. section 1.10(b). "Since the filing of correspondence under section 1.10 without the Express Mail mailing label thereon is an oversight that can be avoided by the exercise of reasonable care, requests for waiver of this requirement will not be granted on petition." Notice of Oct. 24, 1996, 60 Fed. Reg. 56,439, at 56,442.

(Page 1 of 2)

Practitioner's Docket No. 044481-5029-02-US (MPI97-068P1CN1DV1M)

FEE DEFICIENCY

3. If any additional extension and/or fee is required, charge Account No. 501668.
If any additional fee for claims is required, charge Account No. 501668.

May 25, 2004

MILLENNIUM PHARMACEUTICALS, INC.

By: _____

Mario Cloutier
Mario Cloutier

Limited Recognition Under 37 C.F.R. §10.9(b)
40 Landsdowne Street
Cambridge, MA 02139
Telephone - 617-577-3522
Facsimile - 617-551-8820

(Page 2 of 2)

Practitioner's Docket No. MPI97-068P1CN1DV1M

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:	Storm, Daniel R., et al		
Application No.:	10/071,223	Group No.:	1652
Filed:	February 11, 2002	Examiner:	David J. Steadman, Ph.D.
For:	CLONING AND CHARACTERIZATION OF A HUMAN ADENYLYL CYCLASE		

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

REVOCATION OF PRIOR POWERS OF ATTORNEY
AND APPOINTMENT OF NEW POWER OF ATTORNEY

Dear Sir:

MILLENNIUM PHARMACEUTICALS, INC., the Assignee of the entire right, title and interest in the above-identified application by virtue of the Merger document filed with the United States Patent and Trademark Office on June 10, 2002, at Reel 012977, Frame 0516 hereby revokes all Powers of Attorney with respect to that application heretofore granted and appoints the below listed attorneys with full power of substitution and revocation to prosecute this application and to transact all business in the Patent Office connected therewith.

CERTIFICATION UNDER 37 C.F.R. SECTIONS 1.8(a) and 1.10*

I hereby certify that, on the date shown below, this correspondence is being:

MAILING

☐ deposited with the United States Postal Service in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

37 C.F.R. SECTION 1.8(a)

37 C.F.R. SECTION 1.10*

☐ with sufficient postage as first class mail.

☐ as "Express Mail Post Office to Addressee"
Mailing Label No.:

TRANSMISSION

☒ transmitted by facsimile to the Patent and Trademark Office (703) 872 9306


Signature
Simonne Corriveau

(type or print name of person certifying)

Date: 25 May 2004

***WARNING:** Each paper or fee filed by "Express Mail" must have the number of the "Express Mail" mailing label placed thereon prior to mailing. 37 C.F.R. section 1.10(b). "Since the filing of correspondence under section 1.10 without the Express Mail mailing label thereon is an oversight that can be avoided by the exercise of reasonable care, requests for waiver of this requirement will not be granted on petition." Notice of Oct. 24, 1996, 60 Fed. Reg. 56,439, at 56,442.

(Page 1 of 2)

Practitioner's Docket No. MPI97-068P1CN1DV1M

Scott A. Brown	Reg. No. 32,724
Ian R. Silverman	Reg. No. 37,443
Jean M. Silveri	Reg. No. 39,030
Janice M. Klunder	Reg. No. 41,121
Karoline K.M. Shair	Reg. No. 44,332
Kerri Pollard Schray	Reg. No. 47,066
Tracy M. Sioussat	Reg. No. 50,609

all of Millennium Pharmaceuticals, Inc., 40 Landsdowne Street, Cambridge,
Massachusetts 02139, United States of America.

Please direct all future correspondence to:

Customer Number 30405

OR

Intellectual Property Group
MILLENNIUM PHARMACEUTICALS, INC.
40 Landsdowne Street
Cambridge, MA 02139

and direct all telephone calls to Jean M. Silveri at 671-679-7336.

MILLENNIUM PHARMACEUTICALS, INC.

By: _____



Typed Name: Jean M. Silveri

Title: Associate General Counsel

Dated: May 25, 2004

Practitioner's Docket No. 044481-5029-02-US (MPI97-068P1CN1DV1M)

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:	Storm, Daniel R., et al		
Application No.:	10/071,223	Group No.:	1652
Filed	February 11, 2002	Examiner:	David J. Steadman, Ph.D.
For:	CLONING AND CHARACTERIZATION OF A HUMAN ADENYLYL CYCLASE		

Commissioner for Patents
Box 1450
Alexandria, VA 22313-1450

CHANGE OF ATTORNEY DOCKET NUMBER


Dear Sir:

Please note that the Attorney Docket Number has been changed from
044481-5029-02-US to MPI97-068P1CN1DV1M. Please reference MPI97-068P1CN1DV1M on
all future correspondence.

May 25, 2004

Respectfully submitted,
MILLENNIUM PHARMACEUTICALS, INC.

By


Mario Cloutier
Limited Recognition Under 37 C.F.R. §10.9(b)
40 Landsdowne Street
Cambridge, MA 02139
Telephone - 617-577-3522
Facsimile - 617-551-8820

CERTIFICATION UNDER 37 C.F.R. SECTIONS 1.8(a) and 1.10*

I hereby certify that, on the date shown below, this correspondence is being:

MAILING


- ☐ deposited with the United States Postal Service in an envelope addressed to the Commissioner for Patents, Washington, D.C. 20231.
37 C.F.R. SECTION 1.8(a)

37 C.F.R. SECTION 1.10*

- ☐ with sufficient postage as first class mail. ☐ as "Express Mail Post Office to Addressee"
Mailing Label No.

TRANSMISSION

- ☒ transmitted by facsimile to the Patent and Trademark Office to (703) 872 9306.

Signature 
Simonne Corriveau
(type or print name of person certifying)

Date: May 25, 2004

*WARNING: Each paper or fee filed by "Express Mail" must have the number of the "Express Mail" mailing label placed thereon prior to mailing. 37 C.F.R. section 1.10(b). "Since the filing of correspondence under section 1.10 without the Express Mail mailing label thereon is an oversight that can be avoided by the exercise of reasonable care, requests for waiver of this requirement will not be granted on petition." Notice of Oct. 24, 1996, 60 Fed. Reg. 56,439, at 56,442.

(Page 1 of 1)

Practitioner's Docket No. 044481-5029-02-US (MPI97-068P1CN1DV1M)

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Storm, Daniel R., et al.

Application No.: 10/071,223

Group No.: 1652

Filed: February 11, 2002

Examiner: David J. Steadman, Ph.D.

For: CLONING AND CHARACTERIZATION OF A HUMAN ADENYLYL
CYCLASECommissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450ASSOCIATE POWER OF ATTORNEY

Dear Sir:

The undersigned attorney has the power of attorney in the subject application. She hereby grants an associate power to:

Mario Cloutier
Millennium Pharmaceuticals, Inc.
40 Landsdowne Street
Cambridge, MA 02139

CERTIFICATION UNDER 37 C.F.R. SECTIONS 1.8(a) and 1.10*

I hereby certify that, on the date shown below, this correspondence is being:

MAILING

- ☐ deposited with the United States Postal Service in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

37 C.F.R. SECTION 1.8(a)

37 C.F.R. SECTION 1.10*

- ☐ with sufficient postage as first class mail.

- ☐ as "Express Mail Post Office to Addressee"
Mailing Label No. _____

TRANSMISSION

- ☒ transmitted by facsimile to the Patent and Trademark Office to (703) 872-9306.

Signature

Simonne Corriveau

(type or print name of person certifying)

Date: May 25, 2004

*WARNING: Each paper or fee filed by "Express Mail" must have the number of the "Express Mail" mailing label placed thereon prior to mailing. 37 C.F.R. section 1.10(b). "Since the filing of correspondence under section 1.10 without the Express Mail mailing label thereon is an oversight that can be avoided by the exercise of reasonable care, requests for waiver of this requirement will not be granted on petition." Notice of Oct. 24, 1996, 60 Fed. Reg. 56,439, at 56,442.

(Page 1 of 2)

Practitioner's Docket No. 044481-5029-02-US (MPI97-068P1CN1DV1M)

As demonstrated by Appendix A (submitted herewith), Mario Cloutier has passed the Patent Bar Examination and has been granted limited recognition under 37 C.F.R. §10.9(b). Please continue to forward all written and telephonic communications to Jean M. Silveri at the address and telephone number listed below.

Entry of the remarks made herein is respectfully requested.

May 25, 2004

Respectfully submitted,

MILLENNIUM PHARMACEUTICALS, INC.

By



Jean M. Silveri

Registration No. 39,030

40 Landsdowne Street

Cambridge, MA 02139

Telephone - 617-679-7336

Facsimile - 617-551-8820

(Page 2 of 2)